Polaryx Therapeutics, Inc. Common Stock (PLYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has a cash flow conversion efficiency ratio of -0.125x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.37 Million) by net assets ($10.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PLYX company net worth for the company's overall valuation and market capitalisation.
Polaryx Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Polaryx Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Polaryx Therapeutics, Inc. Common Stock debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alkim Alkali Kimya AS
IS:ALKIM
|
0.070x |
|
Farcent Enterprise Co Ltd
TW:1730
|
0.058x |
|
Calida Holding AG
SW:CALN
|
-0.056x |
|
IL Science Co. Ltd
KQ:307180
|
0.100x |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
0.009x |
|
Zeotech Ltd
AU:ZEO
|
-0.080x |
|
ZHEJIANG SHIBAO H YC 1
F:W4K1
|
N/A |
|
Luda Technology Group Limited
NYSE MKT:LUD
|
0.262x |
Annual Cash Flow Conversion Efficiency for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. View PLYX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.57 Million | $-3.94 Million | -0.864x | -58.22% |
| 2024-12-31 | $4.71 Million | $-2.57 Million | -0.546x | -303.07% |
| 2023-12-31 | $1.28 Million | $-173.00K | -0.135x | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more